Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trials.
Lancet Infect Dis. 2024 Mar;24(3):319-328..
Phase I study of the pharmacokinetics and safety of rezafungin in subjects with moderate/severe hepatic impairment and matched control subjects.
Pharmacotherapy. 2024 Jun;44(6):435-443. doi: 10.1002/phar.2943. Epub 2024 Jun 5..
Efficacy and Safety of Rezafungin and Caspofungin in Candidaemia and Invasive Candidiasis: Pooled Data from Two Prospective Randomised Controlled Trials.
Lancet Infect Dis. 2023; S1473-3099(23)00551-0..
Registrational and Pivotal Trial Data
Rezafungin Versus Caspofungin for Treatment Of Candidaemia and Invasive Candidiasis (ReSTORE): A Multicenter, Double-Blind, Double-Dummy, Randomised Phase 3 Trial.
Lancet. 2023;401:49-59..
Efficacy and Safety of Rezafungin and Caspofungin in Candidaemia and Invasive Candidiasis: Pooled Data from Two Prospective Randomised Controlled Trials.
Lancet Infect Dis. 2023; S1473-3099(23)00551-0..
Rezafungin Versus Caspofungin in A Phase 2, Randomized, Double-Blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial.
Clin Infect Dis. 2021;73(11):e3647-55..
In Vitro Microbiology and Pharmacology Studies
Population Pharmacokinetic Modeling and Target Attainment Analyses of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis..
Antimicrob Agents Chemother. 2023 Dec 14;67(12):e0091623.
In Vitro Activity of Rezafungin Against Common and Rare Candida Species and Saccharomyces cerevisiae.
J Antimicrob Chemother. 2019;74(12):3505-3510.
Activity Of CD101, A Long-Acting Echinocandin, Against Clinical Isolates of Candida auris.
Diagn Microbiol Infect Dis. 2018;90(3):196-197.
Absence of Clinically Meaningful Drug-Drug Interactions with Rezafungin: Outcome of Investigations.
Microbiol Spectr. 2023;11(3):e0133923.
Population Pharmacokinetics of Rezafungin in Patients with Fungal Infections.
Antimicrob Agents Chemother. 2021;65(11):e0084221.
Lack of Effect of Rezafungin on QT/Qtc Interval in Healthy Subjects.
Clin Pharmacol Drug Dev. 2020;9(4):456-465.
Population Pharmacokinetic Analyses for Rezafungin (CD101) Efficacy Using Phase 1 Data.
Antimicrob Agents Chemother. 2018;62(6):e02603-17..
Safety and Pharmacokinetics of CD101 IV, a Novel Echinocandin, in Healthy Adults.
Antimicrob Agents Chemother. 2017;61(2):e01627-16..
Metabolism, Excretion, and Mass Balance of [14C]-Rezafungin in Animals and Humans.
Antimicrob Agents Chemother. 2018;66(1):e0139021.
Review Articles
Rezafungin: First Approval.
Drugs. 2023;83(9):833-840.
IDWeek 2023
ECCMID 2023
IDWeek 2022
Registrational and Pivotal Trial Data
Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial.
JAMA. 2018;319(8):788-799..
Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial.
Infect Dis Ther. 2018;7(4):439-455..
Efficacy and Safety of Meropenem-Vaborbactam Versus Best Available Therapy for the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Patients Without Prior Antimicrobial Failure: A Post Hoc Analysis.
Adv Ther. 2019;36(7):1771-1777..
Clinical Outcomes of Patient Subgroups in the TANGO II Study.
Infect Dis Ther. 2021;10(1):35-46.
In Vitro Microbiology and Pharmacology Studies
Meropenem-Vaborbactam Activity against U.S. Multidrug-Resistant Enterobacterales Strains, Including Carbapenem-Resistant Isolates.
Microbiol Spectr. 2023;11(1):e0450722..
Pharmacokinetic-Pharmacodynamic Target Attainment Analyses as Support for Meropenem-Vaborbactam Dosing Regimens and Susceptibility Breakpoints.
Antimicrob Agents Chemother. 2022;66(12):e0213021.
Meropenem-vaborbactam activity against carbapenem-resistant Enterobacterales isolates collected in U.S. hospitals during 2016 to 2018.
Antimicrob Agents Chemother. 2020;64(3):e02177-19..
In vitro Evaluation of Meropenem-Vaborbactam Against Clinical CRE Isolates at a Tertiary Care Center with Low KPC-Mediated Carbapenem Resistance.
Diagn Microbiol Infect Dis. 2019;93(3):258-260.
Pharmacokinetics/Pharmacodynamics of Vaborbactam, A Novel Beta-Lactamase Inhibitor, In Combination with Meropenem.
Antimicrob Agents Chemother. 2018;63(1):e01659-18..
In Vitro Activity of Meropenem-Vaborbactam against Clinical Isolates of KPC-Positive Enterobacteriaceae.
Antimicrob Agents Chemother. 2017;62(1):e01904-17..
Activity of Simulated Human Dosage Regimens of Meropenem and Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in an In Vitro Hollow-Fiber Model.
Antimicrob Agents Chemother. 2018;62(2):e01969-17..
Review Articles
An Appraisal of the Pharmacokinetic and Pharmacodynamic Properties of Meropenem-Vaborbactam.
Infect Dis Ther. 2020;9(4):769-784..
Real-World Studies and Analyses
Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections.
Clin Infect Dis. 2023 Jul 18:ciad428..
ASM Microbe 2017
Registrational and Pivotal Trial Data
Kimyrsa, an Oritavancin-Containing Product: Clinical Study and Review of Properties.
Open Forum Infect Dis. 2022;9(5):ofac090.
Single Intravenous Dose of Oritavancin for Treatment of Acute Skin and Skin Structure Infections caused by Gram-Positive Bacteria: Summary of Safety Analysis from the Phase 3 SOLO studies.
Antimicrob Agents Chemother. 2018;62(4):e01919-17.
Single-Dose Oritavancin in the Treatment of Acute Bacterial Skin Infections.
N Engl J Med. 2014;370(23):2180-90.
Single-Dose Oritavancin versus 7-10 days of Vancomycin in the Treatment of Gram-Positive Acute Bacterial Skin and Skin Structure Infections: The SOLO II Noninferiority Study.
Clin Infect Dis. 2015;60(2):254-62.
In Vitro Microbiology and Pharmacology Studies
Population Pharmacokinetic Analysis for a Single 1,200-milligram Dose of Oritavancin using data from Two Pivotal Phase 3 Clinical Trials.
Antimicrob Agents Chemother. 2015;59(6):3365-72.
Review Articles
Oritavancin (KIMYRSA™) in Acute Bacterial Skin and Skin Structure Infections: A Profile of its Use in the USA.
Drugs & Therapy Perspectives. 2022;38:57-63.
Real-World Studies and Analyses
Comparison of Inpatient Standard-of-Care to Outpatient Oritavancin Therapy for Patients with Acute Uncomplicated Cellulitis.
J Pharm Pract. 2021;36(1):27-32.
Improved Economic and Clinical Outcomes with Oritavancin versus a Comparator Group for Treatment of Acute Bacterial Skin and Skin Structure Infections in a Community Hospital.
PLoS One. 2021;16(3):e0248129.
Early directed Oritavancin therapy in the Emergency Department may lead to Hospital Avoidance compared to Standard Treatment for Acute Bacterial Skin and Skin Structure Infections: A Real-World Retrospective Analysis.
Drugs Real World Outcomes. 2020;7:20-29.
Expediting Discharge in Hospitalized, Adult Patients with Skin and Soft Tissue Infections who received Empiric Vancomycin Therapy with Oritavancin: Description of Findings from an Institutional Pathway.
Drugs Real World Outcomes. 2020;7:30-35.
Comparisons of 30-Day Admission and 30-Day Total Healthcare Costs between patients who were Treated with Oritavancin or Vancomycin for a Skin Infection in the Outpatient setting.
Open Forum Infect Dis. 2019;6(12):ofz475.
IDWeek 2023
Pharmacokinetic and Pharmacodynamic Profiling of Minocycline for Injection Following a Single Infusion in Critically Ill Adults in a Phase IV Open-Label Multicenter Study (ACUMIN).
Antimicrob Agents Chemother. 2021;65(3):e01809-20. .
Registrational and Pivotal Trial Data
A Phase 3 Study to Compare Delafloxacin with Moxifloxacin for the Treatment of Adults with Community-Acquired Bacterial Pneumonia (DEFINE-CABP).
Open Forum Infect Dis. 2019;7(1):ofz514..
Efficacy of Delafloxacin versus Moxifloxacin against Bacterial Respiratory Pathogens in Adults with Community-Acquired Bacterial Pneumonia (CABP): Microbiology Results from the Delafloxacin Phase 3 CABP Trial.
Antimicrob Agents Chemother. 2020;97:374-379..
A Randomized, Double-Blind, Phase 2 Study to Evaluate Subjective and Objective Outcomes in Patients with Acute Bacterial Skin and Skin Structure Infections Treated with Delafloxacin, Linezolid or Vancomycin.
J Antimicrob Chemother. 2016;71(3):821-9..
Analysis of Pooled Phase 3 Safety Data for Delafloxacin in Acute Bacterial Skin and Skin Structure Infections.
Clin Infect Dis. 2019;68(Suppl 3):S233-S240. .
Analysis of Pooled Phase III Efficacy Data for Delafloxacin in Acute Bacterial Skin and Skin Structure Infections.
Clin Infect Dis. 2019;68(Suppl 3):S223-S232..
Efficacy of Delafloxacin Versus Moxifloxacin against Atypical Bacterial Respiratory Pathogens in Adults with Community-Acquired Bacterial Pneumonia (CABP): Data from the Delafloxacin Phase 3 CABP Trial.
Int J Infect Dis. 2020;97:374-379. .
A Comparison of the Efficacy and Safety of Intravenous Followed by Oral Delafloxacin with Vancomycin Plus Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections: A Phase 3, Multinational, Double-Blind, Randomized Study.
Clin Infect Dis. 2018;67(5):657-666. .
In Vitro Microbiology and Pharmacology Studies
In Vitro Activity of Delafloxacin and Microbiological Response against Fluoroquinolone-Susceptible and Nonsusceptible Staphylococcus aureus Isolates from Two Phase 3 Studies of Acute Bacterial Skin and Skin Structure Infections.
Antimicrob Agents Chemother. 2017;61(9):e00772-17..
Review Articles
Delafloxacin: A Review in Community-Acquired Pneumonia.
Drugs. 2022;82(8):913-923. .
Community-Acquired Bacterial Pneumonia-Changing Epidemiology, Resistance Patterns, and Newer Antibiotics: Spotlight on Delafloxacin.
Clin Drug Investig. 2020;40(10):947-960..
Delafloxacin: A Review in Acute Bacterial Skin and Skin Structure Infections.
Drugs. 2020;80(12):1247-1258. .
Real-World Studies and Analyses
Update on the Activity of Delafloxacin against Acute Bacterial Skin and Skin-Structure Infection Isolates from European Hospitals (2014-2019).
J Glob Antimicrob Resist. 2020;23:278-283..
Comparative Efficacy of Delafloxacin for Complicated and Acute Bacterial Skin and Skin Structure Infections: Results from a Network Meta-Analysis.
BMC Infect Dis. 2021;21:1036..
External links on this page are not affiliated with Melinta Therapeutics. Links to sites outside of Melinta are provided as a resource to the viewer. Melinta accepts no responsibility for the content of linked sites. The publications above are intended to share pertinent data regarding Melinta products and associated disease states. The views expressed by the authors are their own, and do not necessarily represent those of Melinta.